Incyte Reports Q3 2026 Financial Results and Raises Full-Year Net Sales Guidance

Executive Summary

On October 29, 2026, Incyte Corporation (NASDAQ: INCY) filed a Form 8-K under Item 2.02 reporting its third-quarter 2026 financial results and updating full-year 2026 guidance.

Key Financial Highlights

• Total Revenue: $1.56 billion for Q3 2026, representing a 14% increase compared to $1.37 billion in Q3 2025.
• Product Net Sales:
  • Jakafi / Jakafi XR: $827 million (+4% YoY).
  • Opzelura Cream: $255 million (+36% YoY).
  • Hematology and Oncology Portfolio: $235 million (+38% YoY).
• Operating Loss: GAAP operating loss was $(708.4) million, compared to GAAP operating income of $443.5 million in Q3 2025. The shift was primarily caused by a one-time $1.23 billion acquired in-process R&D (IPR&D) expense associated with the acquisition of Vega Therapeutics.
• Net Loss / EPS: GAAP net loss of $(784.8) million ($(3.86) per basic and diluted share) compared to net income of $424.2 million ($2.11 per diluted share) in Q3 2025. Non-GAAP net loss was $(730.8) million ($(3.60) per basic share).
• Balance Sheet: Cash, cash equivalents, and marketable securities totaled $3.9 billion as of September 30, 2026.

Updated Full-Year 2026 Guidance

• Total Net Sales: Raised to $5,210 – $5,300 million (previously $5,130 – $5,260 million).
• Opzelura Net Sales: Raised to $1,100 – $1,120 million (previously $1,050 – $1,100 million).
• Hematology and Oncology Net Sales: Raised to $890 – $910 million (previously $860 – $890 million).
• Jakafi Net Sales: Reaffirmed at $3,220 – $3,270 million.
• Operating Expenses: Total GAAP R&D and SG&A guidance unchanged at $4,915 – $4,995 million.